Financial toxicity in lung cancer

被引:9
作者
Boulanger, Mary [1 ]
Mitchell, Carley [2 ]
Zhong, Jeffrey [3 ]
Hsu, Melinda [2 ,3 ]
机构
[1] Johns Hopkins Univ, Dept Med, Baltimore, MD USA
[2] Univ Hosp Seidman Canc Ctr, Dept Oncol, Cleveland, OH 44106 USA
[3] Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
financial toxicity; lung cancer; ASCO value framework; quality of life; survivorship care; COSTS; CARE; DIFFICULTIES; RISK;
D O I
10.3389/fonc.2022.1004102
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the United States, lung cancer is the third most common cancer and the overall leading cause of cancer death. Due to advances in immunotherapy and targeted therapy, 5-year survival is increasing. The growing population of patients with lung cancer and cancer survivors highlights the importance of comprehensive cancer care, including recognizing and addressing financial toxicity. Financial toxicity is a term used to contextualize the negative effects of the costs of cancer treatment in terms of patient quality of life. The American Society of Clinical Oncology (ASCO) Value Framework places emphasis on high-value care as it evaluates cancer treatments "based on clinical benefit, side effects, and improvements in patient symptoms or quality of life in the context of cost". Prior studies have shown that risk factors for financial toxicity in patients with lung cancer include lower household income or savings, inability to afford basic necessities, higher than anticipated out of pocket expenses, and taking sick leave. Among lung cancer survivors, patients experience increased unemployment and lower wages compared to the general population underscoring the lasting effects of financial toxicity. Financial toxicity is associated with increased psychosocial distress and decreased quality of life, and bankruptcy is an independent predictor of mortality in patients with cancer. Despite the negative implications of financial toxicity on patients, standardized screening practices and evidence-based interventions are lacking. The "COmphrensive Score for financial Toxicity (COST)" tool has been validated for assessing financial toxicity with correlation with health-related quality of life. Further research is needed to understand the utility of incorporating routine screening for financial toxicity into clinical practice and the efficacy of interventions. Understanding the relationship between financial toxicity and quality of life and survival is critical to providing high-value cancer care and survivorship care.
引用
收藏
页数:7
相关论文
共 42 条
  • [1] Financial Hardships Experienced by Cancer Survivors: A Systematic Review
    Altice, Cheryl K.
    Banegas, Matthew P.
    Tucker-Seeley, Reginald D.
    Yabroff, K. Robin
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (02):
  • [2] American Cancer Society, 2022, KEY STAT LUNG CANC
  • [3] American Cancer Society, 2020, COSTS CANC CAR 2020
  • [4] Chino Fumiko, 2019, Am Soc Clin Oncol Educ Book, V39, P11, DOI 10.1200/EDBK_100019
  • [5] Going for Broke: A Longitudinal Study of Patient-Reported Financial Sacrifice in Cancer Care
    Chino, Fumiko
    Peppercorn, Jeffrey M.
    Rushing, Christel
    Nicolla, Jonathan
    Kamal, Arif H.
    Altomare, Ivy
    Samsa, Greg
    Zafar, S. Yousuf
    [J]. JOURNAL OF ONCOLOGY PRACTICE, 2018, 14 (09) : 553 - +
  • [6] Development and Validation of Subjective Financial Distress Questionnaire (SFDQ): A Patient Reported Outcome Measure for Assessment of Financial Toxicity Among Radiation Oncology Patients
    Dar, Mukhtar Ahmad
    Chauhan, Richa
    Murti, Krishna
    Trivedi, Vinita
    Dhingra, Sameer
    [J]. FRONTIERS IN ONCOLOGY, 2022, 11
  • [7] Validation of a financial toxicity (FT) grading system.
    De Souza, Jonas A.
    Wroblewski, Kristen
    Proussaloglou, Ellie
    Nicholson, Laura
    Hantel, Andrew
    Wang, Yichen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)
    de Souza, Jonas A.
    Yap, Bonnie J.
    Wroblewski, Kristen
    Blinder, Victoria
    Araujo, Fabiana S.
    Hlubocky, Fay J.
    Nicholas, Lauren H.
    O'Connor, Jeremy M.
    Brockstein, Bruce
    Ratain, Mark J.
    Daugherty, Christopher K.
    Cella, David
    [J]. CANCER, 2017, 123 (03) : 476 - 484
  • [9] The Development of a Financial Toxicity Patient-Reported Outcome in Cancer The COST Measure
    de Souza, Jonas A.
    Yap, Bonnie J.
    Hlubocky, Fay J.
    Wroblewski, Kristen
    Ratain, Mark J.
    Cella, David
    Daugherty, Christopher K.
    [J]. CANCER, 2014, 120 (20) : 3245 - 3253
  • [10] Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions
    Desai, Aakash
    Gyawali, Bishal
    [J]. ECLINICALMEDICINE, 2020, 20